Project: Development and evaluation of a new generation radiopharmaceuticals labeled with Rhenium-188 for the treatment of hepatocellular carcinoma and B-cell non Hodgkin lymphoma

2004-01-01 – 2007-12-31

Abstract

The development of new Re-Lipiodol labelled derivatives with the aid of Re(+1)(CO)3 labellings technique, the developement of anti-CD20 labelled monoclonal antibodies derivatives with new bifunctional chelators containing the Re(+I)(CO)3 core. Development and evaluation of a new generation radiopharmaceuticals labeled with Rhenium-188 for the treatment of hepatocellular carcinoma and B-cell non Hodgkin lymphoma.